Clinical Trial Update: Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Acute Myeloid Leukemia [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating trametinib in combination with the AKT inhibitor GSK2141795 for acute myeloid leukemia was terminated, with results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• GSK2141795 (GSK2141795)
• Trametinib (trametinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Adult Acute Myeloid Leukemia, Untreated Adult Acute Myeloid Leukemia | Phase 2 | Status: TERMINATED | Results posted: 2018-04-06